# A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors

Source: https://onco.cc/trials/nct07131202/  
OnCo record `nct07131202` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of FL115+PD-1 in advanced solid tumours, run by Suzhou Forlong Biotechnology Co., Ltd, now recruiting.

## Summary

A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07131202 by Suzhou Forlong Biotechnology Co., Ltd, with 130 participants planned, started 2026-01-08 and due to reach its primary completion in 2026-12-05. Interventions recorded: FL115+PD-1.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07131202
- Phase: 1/2
- Setting: A Phase Ib/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, Pharmacokinetics, and Pharmacodynamics of FL115 in Combination With a PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors
- Sponsor: Suzhou Forlong Biotechnology Co., Ltd
- Enrolled: 130

## Sources

- ClinicalTrials.gov NCT07131202: https://clinicaltrials.gov/study/NCT07131202

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Suzhou Forlong Biotechnology](https://onco.cc/companies/suzhou-forlong-biotechnology/)

---
JSON: https://onco.cc/api/v1/entities/nct07131202.json